Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

pembrolizumab 86Cyclophosphamide 58Carboplatin 57Specimen Handling 55fludarabine 46Nivolumab 44Magnetic Resonance Spectroscopy 44Gemcitabine 41Biopsy 40Bevacizumab 36Dexamethasone 32venetoclax 31Paclitaxel 29Cisplatin 29Pemetrexed 28Injections 28Docetaxel 26atezolizumab 22Ipilimumab 22Capecitabine 22Temozolomide 21Rituximab 20Oxaliplatin 20Cetuximab 20Azacitidine 20Lenalidomide 19Fulvestrant 19abemaciclib 18Fluorouracil 17Vincristine 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ashwagandha × 90 days × Clear all
NCT05610735 2026-03-19

Combination Therapy for Recurrent Ovarian Cancer

University of Louisville

Phase 1/2 Recruiting
72 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡